Investing.comQwen · 实盘不做把握 3/10不做原因:无增量信息
北京时间·🕒 发布 19:00:27·⟳ 抓取 19:01:19 +52s·⚡ 决策 09-01 19:14:43 +13m24s·56.0 天前
美敦力FY2027一季度财报超预期并上调全年指引，股价盘前涨5%
search_processed_events命中同一具体催化（09-01 11:13 UTC wire源，事件身份、金额、指引完全一致），当时结论为'不做'，理由：千亿美元级公司EPS指引上调幅度有限、Q1受额外一周贡献、缺少高相似先例支撑。当前Investing.com文章仅为该财报的媒体摘要，无新增金额、指引修正或官方确认/否认，不构成新增事实。
📄 原文Investing.com↗ 原文
Medtronic jumps on earnings beat and raised guidance
Fed hike bets, oil rally and Japan yields - what’s moving markets Investing.com -- Medtronic plc (NYSE: MDT) reported f…
不做 Medtronic（MDT.US）
重复消息：同一具体催化（FY27 Q1财报+上调指引）已于11:13 UTC由wire源处理并判定不做。当前Investing.com文章无新增事实。此外，市值~$1200亿、EPS指引仅高于共识0.3%、Q1含额外一周膨胀、盘前已涨5%，短线无剩余edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Medtronic FY27 Q1财报超预期（EPS +$0.06、收入+$0.25B）并上调全年指引，方向正面。但该事件已于12分钟前由wire源完整处理并判定不做：①市值~$1200亿，EPS指引中点仅高于共识0.3%；②Q1含额外一周约$5.7B收入膨胀；③盘前已涨5%基本反映beat。当前Investing.com文章为同一财报的媒体转述，无新增事实，按重复消息处理。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:无需先例支撑，重复消息早停
方向:未执行先例研究，因事件已被同一催化完整处理并判定不做
工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,490 ms
{"result": "search_processed_events:agent query=`mdt earnings raised guidance | medtronic q1 fy2027 earnings beat | 美敦力 财报 超预期 上调指引`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.7/72 小时、2080 条本臂决策(完整)，返回 7 条候选。\n• 09-01 11:13 UTC(CST 19:13) [ticker] 不做 MDT.US (wire) — Medtronic reports first quarter fiscal 2027 resu - fetch_decision_experience 成功 stock_tools HTTP · 610 ms
{ - stock_quote 降级 stock_tools HTTP · 2,047 ms
取价失败: Futu returned no quote
原文全文
展开原文 · 1,755 字
Fed hike bets, oil rally and Japan yields - what’s moving markets
Investing.com -- Medtronic plc (NYSE: MDT) reported first-quarter fiscal 2027 results that exceeded analyst expectations, with shares rising 5% as the medical device maker raised its full-year outlook on strength across its portfolio.
The company posted adjusted EPS of $1.45, beating the consensus estimate of $1.39 by $0.06. Revenue reached $9.8 billion, up 13.7% YoY and ahead of the $9.55 billion analyst estimate.
Medtronic raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75%, up from prior guidance of 6.75% to 7.25%. The company also increased its full-year adjusted EPS guidance to $5.94 to $6.00, with a midpoint of $5.97 slightly above the consensus of $5.95.
The company's strong quarterly performance was broad-based, with the Cardiovascular Portfolio growing 18.9% organically, led by 29.1% growth in Electrophysiology Therapies. Neuroscience grew 9.3% organically, while Medical Surgical increased 10.2%.
"We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms," said Geoff Martha, Medtronic chairman and chief executive officer.
The company noted that fiscal 2027 includes an extra week in the first quarter, which benefited organic growth by approximately $570 million. Adjusted operating margin expanded 10 basis points to 23.7% compared to the prior year period.
Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics during the quarter. The Diabetes business, which the company plans to separate, grew revenue 14.9% organically to $843 million.
Investing.com -- Medtronic plc (NYSE: MDT) reported first-quarter fiscal 2027 results that exceeded analyst expectations, with shares rising 5% as the medical device maker raised its full-year outlook on strength across its portfolio.
The company posted adjusted EPS of $1.45, beating the consensus estimate of $1.39 by $0.06. Revenue reached $9.8 billion, up 13.7% YoY and ahead of the $9.55 billion analyst estimate.
Medtronic raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75%, up from prior guidance of 6.75% to 7.25%. The company also increased its full-year adjusted EPS guidance to $5.94 to $6.00, with a midpoint of $5.97 slightly above the consensus of $5.95.
The company's strong quarterly performance was broad-based, with the Cardiovascular Portfolio growing 18.9% organically, led by 29.1% growth in Electrophysiology Therapies. Neuroscience grew 9.3% organically, while Medical Surgical increased 10.2%.
"We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms," said Geoff Martha, Medtronic chairman and chief executive officer.
The company noted that fiscal 2027 includes an extra week in the first quarter, which benefited organic growth by approximately $570 million. Adjusted operating margin expanded 10 basis points to 23.7% compared to the prior year period.
Medtronic completed acquisitions of Scientia Vascular and SPR Therapeutics during the quarter. The Diabetes business, which the company plans to separate, grew revenue 14.9% organically to $843 million.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。